3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
11
Neoplasms
9
Carcinoma, Hepatocellular
5
Squamous Cell Carcinoma of Head and Neck
4
Melanoma
3
Colorectal Neoplasms
3
Recurrence
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Head and Neck Neoplasms
2
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Solid Tumor, Adult
1
Small Cell Lung Carcinoma
1
Sarcopenia
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Nasopharyngeal Carcinoma
1
Myositis
1
Metastatic Colorectal Adenocarcinoma
1
Lymphoma, Non-Hodgkin
1
Lung Neoplasms
1
Liver Neoplasms
1
Hyperthermia
1
Histiocytoma, Malignant Fibrous
1
Hematologic Neoplasms
1
Heart Diseases
1
Glioma
1
Eye Diseases
1
Esophageal Squamous Cell Carcinoma
1
Interventions
Gemcitabine
3
Albumin-Bound Paclitaxel
3
130-nm albumin-bound paclitaxel
3
Ocoxin
2
Metformin
2
Clomiphene
2
relacorilant
1
pralsetinib
1
pembrolizumab
1
parathyroid hormone-related peptide (1-36)
1
niraparib
1
napabucasin
1
Spironolactone
1
Paclitaxel
1
Octreotide
1
Leuprolide
1
Irinotecan
1
Immune Checkpoint Inhibitors
1
Filgrastim
1
Eating
1
Cisplatin
1
Chorionic Gonadotropin
1
Carboplatin
1
Capecitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Endocrine System Diseases
×
Immune Checkpoint Inhibitors
×
Clear all
NCT03492242
2019-09-26
CHIMeRA
Groupe Hospitalier Pitie-Salpetriere
Completed
1,000 enrolled